If you are interested to learn more about these projects, contact us.
- Oncology NTRC has developed a series of very potent and highly selective inhibitors of the spindle assembly checkpoint kinase TTK, and has identified a genomic biomarker that predicts sensitivity of tumor cells to TTK inhibition. ... Read more
- Cancer Immunotherapy NTRC has discovered a novel series of small molecule inhibitors of IDO1, an enzyme critically involved in the regulation of T cell response in cancer immunotherapy. The compound series was discovered by ultra-high throughput screening at the European Lead Factory using NFK Green™, an assay reagent developed at NTRC. ... Read more
- Parkinson’s disease TDO is a promising new drug target for Parkinson’s disease. NTRC has identified a novel series of selective TDO inhibitors using NFK Green™, a proprietary assay technology for high-throughput screening of tryptophan catabolizing enzymes. ... Read more